TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1750588
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg dihydrocodeine
Study: 17152744
Drug: Luteinising hormone
Normalized name: Luteinising hormone
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinising hormone releasing hormone (100 microg, i.v.)
Study: 17152744
Drug: Thyrotropin (TSH)
Normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin (TSH) releasing hormone (200 microg, i.v.)
Study: 17152744
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (.1 U/kg, i.v.)
Study: 31548349
Drug: Higher plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher plasma 25(OH)D levels (top quintile ≥24.1 ng/mL)
Study: 26179619
Drug: Liraglutide 1.8mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8mg (dose escalated from 0.6 and 1.2mg/day for 1 week each)
Study: 19540671
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine injections
Study: 17468774
Drug: Pre-emptive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive antibiotic therapy (cefepime administered when neutropenia developed)
Study: 17468774
Drug: Pre-emptive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive antibiotic therapy (cefepime)
Study: 17468774
Drug: Empiric antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotic therapy (cefepime administered at onset of fever and neutropenia)
Study: 1684991
Drug: PPA/B (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA/B (75 mg phenylpropanolamine and 12 mg brompheniramine)
Study: 7139401
Drug: etomidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: etomidate 0.3 mg . kg‐1
Study: 19884613
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch plus nicotine lozenge
Study: 26444330
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT - 660 nm, 30 mW, continuous regime, fluency of 10J/cm2) with orthoses
Study: 16139175
Drug: Haloperidol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (up to 8 mg/day)
Study: 10223219
Drug: Sticking plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sticking plaster treatment
Study: 7595911
Drug: Nitrendipine (27.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (27.3 mg daily)
Study: 7595911
Drug: Mefruside (30.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefruside (30.7 mg daily)
Study: 26767505
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg daily for 24 weeks combined with NB-UVB
Study: 26767505
Drug: NB-UVB monotherapy
Normalized name: Nb
DrugBank: Niobium (DB13031)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB-UVB monotherapy
Study: 25185628
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor physical therapy (PFPT) biweekly until 12 weeks postoperatively
Study: 23059199
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy (started at study entry)
Study: 23059199
Drug: Deferred antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred antiretroviral therapy (started when CD4 percentage declined to less than 15%)
Study: 15570025
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (26 +/- 5 g soy protein containing 44 +/- 8 mg isoflavones/d)
Study: 15570025
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate + probiotic capsules (10^9 colony-forming units Lactobacillus acidophilus DDS-1 and Bifidobacterium longum)
Study: 15570025
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein isolate (26 +/- 5 g milk protein/d)
Study: 15570025
Drug: Soy treatments
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy treatments in hypercholesterolemic women (TC > 5.17 mmol/L)
Study: 11482548
Drug: Creatine (3x5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (3x5 g x day(-1))
Study: 11482548
Drug: Iso-nitrogenated placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso-nitrogenated placebo (3x10 g x day(-1))
Study: 7919354
Drug: 150 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/m2 busulfan
Study: 7919354
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg busulfan
Study: 2448408
Drug: Conjugated oral
Normalized name: linoleic acids, conjugated Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated oral estrogens (0.625 mg daily)
Study: 2448408
Drug: Conjugated oral
Normalized name: linoleic acids, conjugated Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated oral estrogens (1.25 mg daily)
Study: 2448408
Drug: Transdermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally administered estradiol (25 micrograms/24 hr)
Study: 2448408
Drug: Transdermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally administered estradiol (50 micrograms/24 hr)
Study: 2448408
Drug: Transdermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally administered estradiol (100 micrograms/24 hr)
Study: 2448408
Drug: Transdermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally administered estradiol (200 micrograms/24 hr)
Study: 30478263
Drug: Low medication
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low medication adherence
Study: 28677237
Drug: Topical Vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Vitamin B12-barrier cream (MB12)
Study: 28677237
Drug: Standard glycerol-petrolatum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glycerol-petrolatum-based emollient cream (GPC)
Study: 26511956
Drug: Motavizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motavizumab (15 mg/kg, five monthly intramuscular doses)
Study: 24386076
Drug: Initial colposcopy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial colposcopy with biopsies and/or subsequent treatment based on colposcopic and histological findings (n = 1696)
Study: 24386076
Drug: Cytological surveillance
Normalized name: OTOLOGICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytological surveillance (six-monthly tests; n = 1703)
Study: 21228029
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets (3.5 mg/kg cumulative dose over 96 weeks)
Study: 21228029
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets (5.25 mg/kg cumulative dose over 96 weeks)
Study: 12895265
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN alpha)-2b + ribavirin (1-1.2 g/day) for 1 year
Study: 12895265
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN alpha)-2b + ribavirin (1-1.2 g/day) at the end of treatment
Study: 12895265
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN alpha)-2b at the end of treatment
Study: 10646156
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam 1 mg before surgery
Study: 10646156
Drug: No sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sublingual lorazepam
Study: 9015118
Drug: Rota colostrum
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rota colostrum (20 ml for 2 weeks)
Study: 6626699
Drug: Methylprednisolone capsule
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone capsule (1 g)
Study: 6626699
Drug: Methylprednisolone suspension
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone suspension (1 g)
Study: 6626699
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of methylprednisolone
Study: 6626699
Drug: High-dose pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pulse therapy
Study: 31556655
Drug: Supportive psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive psychodynamic therapy (SPT)
Study: 25065424
Drug: Ketamine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 8 mg·kg(‐1)
Study: 25065424
Drug: Dexmedetomidine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 3 μg·kg(‐1)
Study: 25065424
Drug: Dexmedetomidine 4
Normalized name: DEXMEDETOMIDINE 4MCG/ML/NS INJ BAG 50ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 4 μg·kg(‐1)
Study: 25065424
Drug: Dexmedetomidine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 5 μg·kg(‐1)
Study: 20923996
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg once daily or 30 mg twice daily)
Study: 17919551
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/d for 3 weeks before surgery
Study: 11226788
Drug: Heparin-surface-modified (HSM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-surface-modified (HSM) PMMA IOL (811C, Pharmacia)
Study: 10806662
Drug: Metformin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (oral administration for 8-12 weeks)
Study: 8282323
Drug: Fludrocortisone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.4 mg/d) treatment with ad libitum diet
Study: 8282323
Drug: Fludrocortisone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.4 mg/d) with a 150 mmol/24 h sodium diet
Study: 179286
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid analogue (antilipolytic agent)
Study: 179286
Drug: Isoprenaline infusion
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline infusion (control for dogs)
Study: 30268158
Drug: Low-frequency electrostimulation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency electrostimulation (ES) administered via CarebandR device on unilateral PC6 acupoint.
Study: 26303188
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (OM)
Study: 22951287
Drug: TAS-102 (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 (35 mg/m² orally twice a day in a 28-day cycle)
Study: 11009140
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg rifampicin
Study: 8866630
Drug: Histamine (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (1% solution) microinjection
Study: 8866630
Drug: Histamine (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (1% solution) combined with oral intake of 20 mg cetirizine
Study: 1324483
Drug: Glucomannan fibers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan fibers (DICOMAN 5:2‐3 gr/die), 2-3 caps twice a day
Study: 31895174
Drug: Sublingual morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual morphine (10 mg)
Study: 31895174
Drug: Swallowed morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowed morphine (10 mg)
Study: 27888177
Drug: Novartis Access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Novartis Access NCD medicines provided through public and private non-profit health facilities.
Study: 27888177
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no access to Novartis Access NCD medicines).
Study: 22344549
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of ondansetron 8 mg orodispersible tablet
Study: 22344549
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of ondansetron 8 mg orodispersible tablet
Study: 17682078
Drug: One-on-one peer
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-on-one peer support (treatment group, n = 37)
Study: 10453931
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g oral ganciclovir daily for 8 weeks
Study: 10453931
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g oral ganciclovir daily for 8 weeks
Study: 7605354
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/day with APOE*2 allele
Study: 7605354
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/day with APOE*3 allele
Study: 7605354
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/day with APOE*4 allele
Study: 26752621
Drug: LY544344 (mGluR2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY544344 (mGluR2/3 agonist)
Study: 25185277
Drug: Nasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal steroid spray (group A)
Study: 25185277
Drug: Nasal irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal irrigation combined with nasal steroid (group C)
Study: 19814624
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide vaccine (PPV)
Study: 19916994
Drug: Individualized dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dosing of enoxaparin
Study: 19916994
Drug: Conventional dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosing of enoxaparin
Study: 19242074
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% Diltiazem ointment
Study: 16356429
Drug: Overtreatment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overtreatment of thyroid hormone replacement
Study: 16356429
Drug: Suboptimal initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Suboptimal initial treatment of thyroid hormone replacement
Study: 16356429
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment factors (free thyroxine and TSH concentrations)
Study: 11977339
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 378 mg/day
Study: 11977339
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiagabine (TGB) 43 mg/g
Study: 9231868
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment for chronic low back pain
Study: 3301444
Drug: Optimized conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized conventional insulin therapy
Study: 27789674
Drug: Neonatal vitamin
Normalized name: NEONATAL VITAMIN Tablet
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal vitamin A supplementation (50,000 IU) among infants born to women who received a mega-dose of vitamin A postpartum
Study: 27789674
Drug: Neonatal vitamin
Normalized name: NEONATAL VITAMIN Tablet
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal vitamin A supplementation (50,000 IU) among infants born to women who did not receive a mega-dose of vitamin A postpartum
Study: 25394474
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy applied to the posterior two‐thirds of the dorsum of the tongue
Study: 25394474
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (tongue scraper and photodynamic therapy)
Study: 20153460
Drug: Residential Interpersonal
Normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential Interpersonal Treatment (RIPT)
Study: 20153460
Drug: Residential Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential Cognitive Treatment (RCT)
Study: 15909190
Drug: Saline infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusions (Control)
Study: 12011543
Drug: Oral telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral telithromycin 800 mg once daily for 5 days (followed by placebo for 5 days), n = 170
Study: 12011543
Drug: Oral telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral telithromycin 800 mg once daily for 10 days, n = 171
Study: 12011543
Drug: Oral telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral telithromycin 800 mg once daily for 5 days
Study: 12011543
Drug: Oral telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral telithromycin 800 mg once daily for 10 days
Study: 9614594
Drug: Doxepin (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (average daily dose: 169.4 ± 41.6 mg)
Study: 9614594
Drug: Fluoxetine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (average daily dose: 36.8 ± 18 mg)
Study: 8593195
Drug: Topical formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulations (including a new stabilized stannous fluoride dentifrice)
Study: 2508382
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition (2,000 kcal/12.4 g N)
Study: 2508382
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (1,940 kcal/12.4 g N)
Study: 22013492
Drug: Triple-target treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-target treatment (3T)
Study: 17183987
Drug: Heparin (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (unfractionated or low-molecular weight)
Study: 12657165
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetaminophen, given 6 times daily during 5 days
Study: 12657165
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen, given 6 times daily during 5 days
Study: 12657165
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given 6 times daily during 5 days
Study: 9496390
Drug: Pamidronate 120
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate 120 mg
Study: 9064108
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg and 120 mg
Study: 1722512
Drug: Parenteral gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral gold therapy combined with 120 mg intramuscular methylprednisolone acetate at Weeks 0, 4 and 8
Study: 6357930
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg three times daily
Study: 6357930
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg four times daily
Study: 27639387
Drug: Acotiamide 100
Normalized name: acetiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acotiamide 100 mg × 3/day for 2 weeks
Study: 27107325
Drug: Mid-luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-luteal phase surgical oophorectomy + oral tamoxifen
Study: 27107325
Drug: Mid-follicular phase
Normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mid-follicular phase surgical oophorectomy + oral tamoxifen
Study: 27107325
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase surgery patients with progesterone levels <2 ng/ml
Study: 27107325
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase surgery patients with progesterone levels ≥2 ng/ml
Study: 21733056
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate 1000 mg QD
Study: 21733056
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate 1000 mg BID
Study: 15774786
Drug: RT-first (radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT-first (radiation therapy before chemotherapy)
Study: 31680023
Drug: Mindfulness-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based therapy (MBT) for PNES, 12 sessions
Study: 24104532
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 15 mg 0.5% hyperbaric bupivacaine intrathecally
Study: 24104532
Drug: Iliohypogastric ilioinguinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iliohypogastric ilioinguinal nerve block (IHNB) with 20 mL 0.5% plain bupivacaine
Study: 11384804
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg daily for 6 months)
Study: 8357888
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use (including prescription and nonprescription)
Study: 8357888
Drug: Multiple medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple medication use